<?xml version="1.0" encoding="UTF-8"?>
<p>The key inclusion criteria included: (i) age of 20‐79 years; (ii) histological or cytological diagnosis of PTCL or CTCL; (iii) relapsed or refractory disease after systemic therapy, including psoralen‐UV A radiation and retinoid; (iv) adequate renal (serum creatinine ≤1.5× ULN or calculated creatinine clearance ≥50 mL/min), hepatic (total bilirubin ≤1.5× ULN, serum albumin ≥3.0 g/dL, and AST or ALT ≤3.0× ULN) and hematologic (absolute neutrophil count ≥1.0×10
 <xref rid="cas13513-bib-0003" ref-type="ref">3</xref>/μL, platelet count ≥5.0 × 10
 <xref rid="cas13513-bib-0004" ref-type="ref">4</xref>/μL, and hemoglobin ≥8.0 g/dL) functions; (v) ECOG performance status of 0 or 1; and (vi) a life expectancy ≥3 months. The key exclusion criteria included: (i) central nervous system invasion with clinical symptoms or requiring treatment; (ii) serious or severe active infection requiring treatment; (iii) prior radiotherapy and chemotherapy within 4 weeks; (iv) prior antibody therapy within 3 months; (v) history of hypersensitivity to therapeutic protein; (vi) pleural effusions; (vii) relapse within 6 months of autologous hematopoietic stem cell transplantation; (viii) history of allogeneic hematopoietic stem cell transplantation; and (ix) pregnancy or breastfeeding. This study was undertaken in compliance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. The study protocol was approved by the institutional review board of each institution, and all patients provided written informed consent prior to any study procedure.
</p>
